A PHASE 2A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MK-8690 IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
- Registry ID
- MK-8690-002
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- MERCK CANADA INC
- Start date
- 2026-08-13
- Last update
- 2026-04-24
Conditions
Related clinical trials
- A PHASE 3 RANDOMIZED, DOUBLE-BLIND, AND ACTIVE-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF JNJ-78934804 IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
- A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
- A PHASE 2 OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE THE EFFICACY, PHARMACOKINETICS, AND SAFETY OF ETRASIMOD IN PEDIATRIC PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
- A MULTICENTER, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY OF DUVAKITAG IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE PHASE 3, MAINTENANCE STUDY TO EVALUATE THE EFFICACY AND ULCERATIVE COLITIS.
- A MULTICENTER, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3, INDUCTION STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUVAKITUG IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
- A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN HEALTHY PARTICIPANTS FOLLOWED BY A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CPNTROLLED PHASE 2 STUDY IN PARTICIPANTS WITH MODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS
View on source registry